



Article scientifique

Article

2013

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

Update on the protective molecular pathways improving pancreatic beta-cell dysfunction

Puddu, Alessandra; Sanguineti, Roberta; Mach, François; Dallegri, Franco; Viviani, Giorgio Luciano; Montecucco, Fabrizio

How to cite

PUDDU, Alessandra et al. Update on the protective molecular pathways improving pancreatic beta-cell dysfunction. In: Mediators of inflammation, 2013, vol. 2013, p. 750540. doi: 10.1155/2013/750540

This publication URL: <https://archive-ouverte.unige.ch/unige:77513>

Publication DOI: [10.1155/2013/750540](https://doi.org/10.1155/2013/750540)

Review Article

Update on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction

Alessandra Puddu,¹ Roberta Sanguineti,¹ François Mach,² Franco Dallegri,³ Giorgio Luciano Viviani,¹ and Fabrizio Montecucco^{2,3}

¹ Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genova, Italy

² Division of Cardiology, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva 4, Switzerland

³ First Medical Clinic, Laboratory of Phagocyte Physiopathology and Inflammation, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genova, Italy

Correspondence should be addressed to Fabrizio Montecucco; fabrizio.montecucco@unige.ch

Received 5 February 2013; Accepted 10 April 2013

Academic Editor: Oreste Gualillo

Copyright © 2013 Alessandra Puddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The primary function of pancreatic beta-cells is to produce and release insulin in response to increment in extracellular glucose concentrations, thus maintaining glucose homeostasis. Deficient beta-cell function can have profound metabolic consequences, leading to the development of hyperglycemia and, ultimately, diabetes mellitus. Therefore, strategies targeting the maintenance of the normal function and protecting pancreatic beta-cells from injury or death might be crucial in the treatment of diabetes. This narrative review will update evidence from the recently identified molecular regulators preserving beta-cell mass and function recovery in order to suggest potential therapeutic targets against diabetes. This review will also highlight the relevance for novel molecular pathways potentially improving beta-cell dysfunction.

1. Introduction

Pancreatic beta-cells are principally responsible for the transcription of the gene encoding insulin and the subsequent processing and secretion of insulin in response to increases in extracellular glucose concentrations [1]. Their dysfunction induces profound metabolic consequences, leading to the development of hyperglycemia and, ultimately, diabetes mellitus [2]. In type 2 diabetes, the reduction in beta-cell function is associated with the loss of glucose-stimulated insulin secretion (GSIS) and the reduction of beta-cell mass [3, 4]. Insulin secretion is a complex mechanism with multiple points of regulation [5]. Briefly, glucose is transported into beta-cells by the high-capacity glucose transporter (GLUT) and metabolized by glucokinase that generates glucose-6-phosphate. Furthermore, glycolytic and oxidative metabolism of glucose results in the elevation of the cytosolic ATP/ADP ratio, which drives to blockade of the ATP-sensitive potassium channels.

The inhibition of the ATP-sensitive potassium channels causes the depolarization of the plasma membrane that triggers the opening of the voltage-gated calcium channels. The increased intracellular calcium concentration allows the fusion of insulin-containing granules with plasma membrane and the subsequent release of stored insulin through interactions with Ca^{2+} -sensitive proteins. The loss of acute GSIS is accompanied by marked changes in beta cell phenotype and changes in gene and protein expression [6–8]. Although the cause of this metabolic deterioration is unknown, several hypotheses have been proposed. The worsening of beta-cell function over time creates a vicious cycle by which metabolic abnormalities impair insulin secretion, which further aggravates metabolic perturbations [9–11]. Indeed, the diabetic milieu is enriched with high levels of glucose, advanced glycation end-products (AGEs), proinflammatory cytokines, free fatty acids, and other lipid intermediates [12, 13]. These factors are toxic for beta-cells and might activate several stress

response pathways, including oxidative and endoplasmic reticulum (ER) stress, mitochondrial dysfunction, apoptosis, and necrosis [14].

The molecular pathways regulating insulin secretion are also implicated in the beta-cell turnover. Therefore, the more recent research field in diabetes focused on therapeutic approaches to recover both beta-cell function and preservation as a strategy to reverse the metabolic consequences of insulin deficiency. Here, we reviewed the emerging evidence regarding molecular pathways that might be involved in improving beta-cell dysfunction.

2. Soluble Extracellular Molecules and Drugs Improving Beta-Cell Function

2.1. Glucagon-Like Peptide-1 (GLP-1). The decline in beta cell function in type 2 diabetes is directly associated with impaired action of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and GLP-1. These hormones are secreted from the intestine in response to energy intake and glucose and may potentiate as much as 70% of the meal-induced insulin response in healthy individuals. The impairment of GLP-1 secretion is one of the most relevant pathophysiological alterations in T2DM. The recently developed treatment against diabetes, based on GLP-1 receptor agonists or dipeptidyl peptidase-4 (DPP4) inhibitors (the enzyme responsible of GLP-1 inactivation), have been shown to induce beneficial effects on beta cell function [15–21]. These biological effects of GLP-1 are selectively mediated by binding to its receptor, GLP-1R, a specific seven-transmembrane receptor guanine nucleotide-binding protein (G-protein) coupled receptor (GPCR), which is widely distributed in pancreatic islets, brain, heart, kidney, and the gastrointestinal tract [22]. In the pancreas, GLP-1 has been shown to potentiate glucose-induced insulin secretion, improve pancreatic beta-cell neogenesis and proliferation, reduce beta-cell apoptosis, inhibit glucagon secretion from pancreatic alpha-cells, restoring glucose homeostasis [23, 24]. GLP-1 also acts synergistically with glucose to promote insulin gene transcription, mRNA stability, and biosynthesis, increasing the expression of the transcription factor Pancreas duodenum homeobox-1 (Pdx-1) and the binding of this factor to the insulin promoter. Furthermore, GLP-1 confers glucose sensitivity to glucose-resistant beta-cells, thereby improving their capacity to sense and respond to glucose. The cyclic AMP (cAMP) signaling pathway is central in transducing GLP-1-mediated activities in beta-cells. In fact, GLP-1 has been shown to improve both beta-cell proliferation and survival via the cAMP-dependent stimulation of the cAMP response element-binding protein (CREB) [25–27]. These promising results were confirmed *in vivo* in obese diabetic (db/db) mice. The prolonged treatment with GLP-1 enhanced not only insulin secretion, but also beta-cell neogenesis and islet size [28]. Accordingly, Buteau and coworkers demonstrated that beta-cell apoptosis induced by glucose and lipotoxicity was prevented by GLP-1 treatment [29]. Recently, evidence from our laboratory confirmed that GLP-1 counteracted the detrimental effects of advanced glycation

end-products (AGEs) on pancreatic beta-cells, preserving both function and survival [30]. In particular, we showed that GLP-1 ameliorated glucose-induced insulin secretion and antioxidant defense and restored expression of transcriptional factors that regulate insulin gene expression.

Considering that GLP-1 is rapidly inactivated by the ubiquitous proteolytic enzyme DPP4, its therapeutic use has been partially limited. More recently, the concomitant administration of DPP4 inhibitors or the identification of more stable exogenous GLP-1R agonists has improved clinical efficacy of incretin treatments [31–35]. In particular, DPP4 inhibition has been shown to approximately double the circulating GLP-1 levels, while synthetic agonists mimicking GLP-1 action resulted in striking elevations of GLP-1 signaling [36].

2.2. Metformin. Metformin is an antidiabetic drug commonly used since the 1960s to treat type 2 diabetes [37]. The oral absorption, hepatic uptake, and renal excretion of metformin are mediated by organic cation transporters (OCTs) [38, 39]. The glucose-lowering properties are primarily due to the reduction in the hepatic glucose production and increase in insulin-stimulated glucose uptake within the muscle and fat tissues. These effects are mediated by the activation of AMP-activated protein kinase (AMPK) [40] and the inhibition of complex I in the mitochondrial respiratory chain [41, 42]. Metformin is widely used in combination with both DPP4 inhibitors and GLP-1 agonists to further suppress the hepatic production of glucose. Maida and coworkers demonstrated that metformin enhanced *in vitro* the expression of GLP-1R, via a peroxisome proliferator-activated receptor (PPAR- α) dependent pathway, improving incretin-mediated bioactivity [43]. Moreover, in rat pancreatic islets whose secretory function has been impaired by the chronic exposure to elevated FFA or glucose levels, metformin was able to restore a normal insulin secretory pattern [44]. On the other hand, the incubation of isolated T2D islets with metformin was associated with increased insulin content and release and reduced apoptosis [45]. Kefas and colleagues demonstrated that metformin dose-dependently also activates AMPK in insulin-producing MIN6 cells and in primary rat beta-cells, leading to increased phosphorylation of acetyl coA carboxylase (ACC) [46]. This chronic stimulation reduced the secretory and synthetic responsiveness of rat beta-cells to glucose and resulted in a progressive increase of apoptosis due to metformin-activated c-Jun-N-terminal kinase (JNK) and caspase-3 [47]. These controversial effects on insulin secretion and susceptibility to apoptosis might be related to the high drug concentrations that are not achieved *in vivo* [48, 49].

2.3. Thiazolidinediones. The thiazolidinediones (pioglitazone, rosiglitazone, and troglitazone), also known as glitazones, are a class of drugs used in the treatment of type 2 diabetes mellitus, which acts by activating the group of nuclear receptors peroxisome proliferator-activated receptors (PPARs), with greatest specificity for PPAR γ [50]. After activation, these receptors bind to DNA in complex with

the retinoid X receptor (RXR), thus regulating transcription of several specific genes. The major clinical impact of thiazolidinediones is to improve insulin sensitivity, thereby increasing glucose uptake and reducing hepatic glucose output [51]. In addition to the insulin sensitizing effect, there is growing body of evidence indicating that thiazolidinediones preserve pancreatic beta-cell mass and function [52]. Activation of PPAR γ protects pancreatic beta-cells from cytotoxicity preventing nuclear factor- κ B (NF- κ B) activation [53–55]. On the other hand, pioglitazone has been shown to improve insulin secretory capacity in both diabetic humans and mice [56, 57]. In particular, treatment with this drug prevented the loss of beta-cell mass in murine diabetes and preserved human islets against glucose-induced apoptosis [58–60]. Rosiglitazone was shown to protect pancreatic islets from the apoptosis in the presence of islet amyloid polypeptide fibrils via a PI3K-Akt pathway [61]. Treatment with pioglitazone prevented the loss of the sarcoendoplasmic reticulum Ca²⁺ ATPase (SERCA) pump induced by high glucose concentration and proinflammatory cytokine interleukin-1 β (IL-1 β), thus favoring the maintenance the intracellular Ca²⁺ homeostasis in the pancreatic beta-cells [62]. Recently, we showed that treatment with pioglitazone restored the redox balance, improved the responsiveness to low glucose concentration, and protected cells against apoptosis and necrosis in pancreatic beta-cells exposed to advanced glycation end-products (AGEs) [63].

3. Intracellular Targets: Cytosolic Molecules Protecting Beta-Cell Homeostasis

3.1. Akt. The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a major downstream effector of the phosphoinositide 3-kinase (PI3K) signalling pathway, activated by numerous growth factors and hormones such as insulin [64]. Akt activity consists of multiple steps that involve membrane translocation and phosphorylation [65]. Akt/PKB translocation to the nucleus results in phosphorylation of many substrates that control various biological processes. Activation of Akt signaling in transgenic mice constitutively overexpressing activated Akt in beta-cells resulted in increased islet mass, largely due to neogenesis and proliferation of beta-cells, and improved glucose tolerance [66, 67]. Alterations in Akt signaling play an important role in beta-cell adaptation to the increase of insulin demand. Indeed, reduction of Akt activity in transgenic animals expressing a kinase-dead mutant of Akt in beta-cells resulted in impaired glucose tolerance due to defective insulin secretion [68]. PI3K/Akt signalling might be a converging pathway in the regulation of beta-cell mass by growth factors, insulin, incretins, and glucose [69]. Maintenance of beta-cell mass results predominantly from proliferation of preexisting beta-cells and required the activation of the cyclins D2, and D1 [70–72]. Indeed, Akt activates beta-cell proliferation in a cdk4-dependent manner by inducing cyclin D1, D2 and p21Cip1 [73]. It is well known that the IRS2/PI3K/Akt signaling pathway is a crucial regulator of beta-cell mass and function [74, 75]. Therefore, the serine-threonine kinase

Akt might represent one of the potential targets to improve beta-cell proliferation and survival. Protective incretins may activate Akt by induction of PI3K signalling in INS-1 cells and islets [76, 77]. The mechanisms involved in this process have been partially elucidated, but there is evidence that GLP-1 might promote transactivation of the epidermal growth factor receptor (EGFR) [78, 79]. GLP-1 receptor agonists could also indirectly modulate Akt signalling by activating cAMP-dependent pathways leading to the final increased transcription of IRS2 [80]. Several studies using beta-cell lines have shown the importance of Akt also for cell survival. *In vitro* experiments using insulinoma cell lines and isolated islets demonstrated that Akt activation by glucose, insulin, insulin growth factor (IGF)-1, and GLP-1 is a major determinant for the antiapoptotic effects of these molecules [23, 81, 82]. The expression of a constitutively active form of Akt in INS1 cells prevented free fatty acid-induced apoptosis and modulates survival to ER stress [83].

3.2. Molecules Involved in Unfolded Protein Response. As the main function of beta-cells is the production and secretion of insulin, the endoplasmic reticulum (ER) is very well developed and highly active in order to produce insulin even under high demand. However, these properties also likely increase the susceptibility of these cells to ER stressors, which might produce signals mediating glucose-induced impairment of function and death. Increasing experimental evidence suggests ER stress to be a relevant cause in the progressive beta-cell failure and apoptosis [84–86]. When misfolded proteins accumulate within their ER, eukaryotic cells trigger an unfolded protein response (UPR) or ER stress response, leading to an increase of chaperone gene transcription [87, 88]. The main purpose of the UPR is to restore ER homeostasis by decreasing protein load and increasing its folding capacity. The signaling pathways engaged following ER stress are complex and involve three transmembrane stress sensors: activating transcription factor 6 (ATF6), inositol requiring-1 (IRE1), and double-stranded RNA-activated protein kinase- (PKR-) like kinase (PERK), that activate genes increasing the protein folding capacity and concomitantly decrease the load of proteins entering the ER [89–91]. Indeed, the modulation of the expression of ER chaperones and the use of exogenous chemical chaperones may represent useful strategies in counteracting the ER stress pattern [92–96]. The identification of pathways alleviating beta-cell ER stress might have a considerable clinical impact on diabetes. Interestingly, it has been found that GLP-1R agonists potentiate expression of gene products subjected to the UPR in response to ER stress. Indeed, the activation of GLP-1R has been shown to stimulate the PERK arm of the UPR in both rat primary beta-cells and INS-1 cells, thus favoring beta-cell adaptation to metabolic and cellular stress [97]. In particular, the GLP-1R agonist exendin-4 attenuated the translational downregulation of insulin and improved *in vitro* cell survival following ER stress, thus shifting from translational repression to the recovery phase [98]. Furthermore Cunha and coworkers demonstrated that Exendin-4 protected pancreatic beta-cells from ER stress increasing

the expression of binding immunoglobulin-protein (Bip), a key ATF6-dependent ER chaperone [97].

3.3. Calcium. The divalent cation Ca^{2+} plays an important role in several aspects of the beta-cell physiology. GSIS occurs through a Ca^{2+} -dependent mechanism coupling cellular depolarization with cytosolic Ca^{2+} influx from voltage-gated Ca^{2+} channels and insulin granule exocytosis [99, 100]. In addition to this central role in the secretory response, Ca^{2+} homeostasis is important in ER function, including protein folding and maturation [101, 102]. In particular, the maintenance of a robust pool of Ca^{2+} in the ER plays a key role in several aspects of beta-cell function including insulin production and secretion and the maintenance of ER health. The flux of Ca^{2+} across the ER is regulated by SERCA2b, a pump resident in the ER membrane, that hydrolyzes one ATP molecule to move two Ca^{2+} molecules across the sarco- or ER membrane [103]. Inhibition of SERCA2b reduced the efflux of Ca^{2+} from the ER and leads to activation of the UPR [104]. Evidence that SERCA2b expression in pancreatic beta-cells is decreased in selected models of diabetes has emerged from several studies [105–107]. Moreover, SERCA2b is downregulated in rodent diabetic or human islets isolated from cadaveric T2DM diabetic donors [62]. *In vitro* experiments demonstrate that the thiazolidinedione pioglitazone preserves SERCA2b expression in the presence of high glucose concentrations (25 mM) and inflammatory cytokines, through modulation of cyclin-dependent kinase 5 activity and PPAR- γ phosphorylation [62]. Expression of SERCA is also preserved by exendin-4 through a PKA-dependent pathway [108].

3.4. Glucokinase. Glucokinase (GK) is an enzyme that phosphorylates glucose [109]. Since GK activity has been related to the induction of insulin secretion, GK is considered as a “glucose sensor” in pancreatic beta-cells. It has been reported that a mutation in GK can lead to maturity onset of diabetes mellitus in young (MODY) [110, 111]. Moreover, GK^{+/-} mice showed decreased beta-cell replication and impaired insulin secretion in response to glucose, suggesting that GK regulates pancreatic beta-cell mass as well as their function [112]. The induction of the glycation reaction, which is known to occur in pancreatic beta-cells in chronic hyperglycaemia, suppresses the glucokinase gene transcription and its enzymatic activity [113]. Therefore, pancreatic beta-cell function may be improved by the activation of GK. The identification of GK pharmacological activators has started in 2001 and showed from the beginning a high potential to improve current treatment of type 2 diabetes mellitus [114]. In addition, posttranslational activation of GK is an important mechanism for mediating the insulinotropic effects of GLP-1 [115]. Moreover, exendin-4 has been shown to stimulate GK expression within the pancreatic beta-cell line INS-1 via a Ca^{2+} /calmodulin- (CaM-) dependent protein kinase cascade [116].

3.5. Reactive Oxygen Species (ROS). The dynamic, fluctuating activation of stress signalling is required for the maintenance

of survival, whereas its persistent activation results in dysfunction and apoptosis of pancreatic beta-cells. The relatively low expression and activity of many enzymes involved in the antioxidant defense renders beta-cells highly susceptible to oxidative damage [117]. In particular, reactive oxygen species (ROS, such as superoxide anion and hydrogen peroxide), might contribute to beta-cell dysfunction [118–120]. ROS may originate during cellular metabolic processes or may be introduced via toxic extracellular mediators. Mitochondria are an important intracellular source of ROS, and, in turn, also a target of ROS-mediated injury. Superoxide anion is a very reactive molecule, which can be converted to less reactive H_2O_2 by superoxide dismutase (SOD) isoenzymes, and then to oxygen and water mainly by catalase (CAT), glutathione peroxidases (GPxs), and peroxiredoxin [121]. The levels of the H_2O_2 -inactivating enzymes GPxs and CAT are extremely low in pancreatic beta-cells [117]. Therefore, their defense against ROS toxicity is very limited. The transcription factor NF-E2-related factor 2 (Nrf2) [122] is one of the major antioxidant pathway allowing the synthesis of many protective enzymes [123]. Accumulating evidence suggests important connections between Nrf2, PPAR γ , and PI3K/Akt on regulating antioxidant enzymes in diabetes [124]. Glutathione remains the most important intracellular defense against ROS [125, 126], implying that the ratio of the oxidized form of glutathione (GSSG) and the reduced form (GSH) is considered as a dynamic indicator of the oxidative stress of an organism. It has also been reported that glucose metabolism might increase the ROS-scavenger potential of the pancreatic beta-cells through generation of NAD(P)H, and that this effect seems to be more pronounced in beta-cells with higher metabolic responsiveness to glucose [127].

In pancreatic beta-cells, ROS generation is not only a harmful process but, rather, plays a substantial role in the normal insulin signal transduction and might be one of the metabolic signals stimulating insulin secretion. Indeed, in pancreatic beta-cells ROS generation might also occur in response to glucose stimulation [128, 129], as a consequence of glycolytic and oxidative events leading to accelerated ATP generation. In particular, Pi and coworkers demonstrated that glucose-induced intracellular H_2O_2 accumulation coincides with glucose-stimulated insulin secretion [130]. Considering that the role of H_2O_2 in glucose-stimulated insulin secretion is controversial, Lortz and colleagues recently reported that the overexpression of the H_2O_2 inactivating enzyme catalase did not affect insulin secretion in response to glucose [131]. These discrepancies might be explained by the different time of incubation and culture conditions. Indeed, the study by Leloup and coworkers showed that transient mitochondrial ROS production is required for glucose-induced insulin secretion [132]. This implies that the ROS levels need to be finely regulated to keep “good” instead of “bad” radicals, thus avoiding oxidative damages.

3.6. MicroRNAs. MicroRNAs (miRNAs) are small nucleotide noncoding RNA molecules, which regulate gene expression by inhibiting translation or inducing target mRNA degradation [133–135]. The role of miRNAs in beta-cell mass

regulation is not fully understood. However, it has been suggested that miRNAs target genes are important for pancreas development, beta-cell proliferation, insulin secretion, and exocytosis [136]. Several recent studies suggested that the modulation of miRNA expression could be of interest for novel treatments against diabetes. MicroRNA-375 (miR-375) is necessary for the proper formation of pancreatic islets in vertebrates and is necessary for the development of beta-cells in mice [137, 138]. The specific knockdown of miR-24, miR-26, miR-182, or miR-148 in cultured beta-cells or in isolated primary islets downregulated insulin promoter activity and mRNA levels [139, 140]. Among different miRNAs, miR-9 has been shown to regulate exocytosis in beta-cells [141]; miR-30d induced insulin gene expression in pancreatic beta-cells, associated with increased expression of MafA, a beta-cell specific transcription factor [142]. On the other hand, the overexpression of miR-21 downregulated proteins involved in insulin secretion [143], while the overexpression of other miRNAs (such as miR-33a, miR-375, and miR-29a/b/c), lead to impairment in glucose-induced insulin secretion [144–146].

4. Nuclear Factors

The specialized features of beta-cells are determined by the expression of a gene subset controlled by a variety of transcription factors. Insulin production is achieved by a strict regulation of insulin synthesis and exocytosis at the transcriptional and posttranscriptional levels, mainly regulated by blood glucose concentration [147–149]. The activity of beta-cell transcription factors is modulated at a multiple upstream level including subcellular localization, DNA-binding activity, transactivation capability, and interaction with other proteins.

Among the numerous transcription factors implicated in the regulation of insulin transcription, V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), Pancreatic and duodenal homeobox 1 (Pdx-1), forkhead box protein O1 (FoxO1), and nuclear factor E2-related factor 2 (Nrf2) have been demonstrated to play a crucial role in pancreatic beta-cell function [147, 149].

5. MafA

MafA is a basic leucine zipper transcription factor belonging to the large Maf family of transcription factors. In pancreatic beta-cells, MafA has been shown to play an important role in glucose regulation of insulin gene expression and in mediating the expression of a number of other genes, including PDX-1 [149–151]. MafA levels in beta-cells might be regulated by posttranscriptional mechanisms, such as the phosphorylation of two residues (serines 14 and 65) located in the transcriptional activating domain by the mitogen-activated protein kinase 1 (also known as MAPK1 or ERK2). The expression of MafA is observed at later stage of beta-cell development suggesting a role for MafA as crucial master regulator of genes implicated in maintaining beta-cell function in response to glucose [152].

MafA knockout mice are viable, but develop diabetes during life as a result of the decreased insulin secretion from beta-cells and alteration of islet architecture [147, 152, 153].

Recently, biochemical studies revealed that FoxO1 and PDX-1 bind directly to the MafA promoter and mediate MafA transcription [149], suggesting that different transcription factors might regulate insulin regulation within beta-cells.

Enhanced production of MafA under high-glucose concentrations may regulate the glucose-dependent transcription of the insulin gene, whereas decreased production or proteasomal degradation of MafA probably rapidly inhibited insulin transcription. These results suggest that MafA upregulation within beta-cells should precede the insulin transcription process [153]. The downregulation of the expression of MafA gene has been observed in the presence of lipotoxicity as well as exposure to proinflammatory cytokines [152, 154, 155].

All these results indicate that MafA may be qualified as a crucial master regulator of genes implicated in maintaining beta-cell function and glucose-stimulated insulin synthesis. Its modulation may represent a key therapeutic target to prevent beta-cell dysfunction in response to injury [152].

6. PDX-1

The pancreatic and duodenal homeobox 1 (PDX-1) is critical in both beta-cell development and function [149, 152]. Similar to MafA, it is considered as a major regulator of glucose-stimulated insulin gene transcription. PDX-1 could be regulated at the transcriptional, posttranscriptional, and translational level and its expression is conditioned by several mechanisms of beta-cell damage (such as glucotoxicity, lipotoxicity, oxidative stress, and inflammation) [147]. The subcellular localization of PDX-1 has been shown to be regulated by the changes in glucose levels. When exposed to low glucose concentrations, PDX-1 is mainly localized to the nuclear periphery and associated with histone deacetylase-1 and -2 (HDAC-1 and HDAC-2) and does not interfere with insulin gene expression. In the presence of increased glucose levels, PDX-1 promotes shuttle to the nucleoplasm of its phosphorylated form and becomes associated with the histone acetyltransferase (HAT) p300, leading to hyperacetylation of histone H4 and induction of insulin gene transcription [147, 156, 157].

Therefore, the downregulation of PDX-1 importantly affects insulin production favoring beta-cell secretory dysfunction and potentially diabetes [158]. As an example, ROS have been described to potently inhibit PDX-1 in beta-cells [159–162]. Indeed, various studies have shown that oxidative stress inhibits Pdx-1 nuclear localization and DNA binding through the activation of the c-Jun N-terminal kinase (JNK) pathway [149, 163].

As reported by Robertson and coworkers using a pancreatic islet cell line HIT-T15, the generation of ROS might cause the loss of PDX-1 protein as a consequence of the posttranscriptional loss of PDX-1 mRNA [12, 164]. More recently, Tingting and colleagues reported that the exposure to AGEs in INS-1 cells decreased PDX-1 protein levels without

a decrement in PDX-1 mRNA level and promoter activity. Therefore, PDX-1 protein expression deficiency might be not due to the inhibition of its transcription, but potentially to the decrease in its protein stability related to its nucleocytoplasmic translocation [158, 165].

Several studies suggest that PDX-1 may serve as a target for other posttranscriptional and posttranslational modifications, such as glycosylation. Gao and coworkers demonstrated that PDX-1 was also modified by O-linked N-acetylglucosamine (O-GlcNAc), with a consequent positive association between protein O-GlcNAcylation, PDX-1 DNA-binding activity, and insulin secretion. These data indicate that this ubiquitous nucleocytoplasmic saccharide modification might participate to the regulation of insulin gene expression and it may be involved in the development of insulin resistance within the beta-cells or peripheral tissues [166].

As discussed above, GLP-1 agonists have been shown to improve beta-cell morphology and function. GLP-1-mediated pathways of beta-cell protection can act at nuclear level involving the regulation of PDX-1. Indeed, GLP-1 directly increased PDX-1 levels and its nuclear localization, enhancing its DNA-binding activity [26, 167, 168].

Importantly, Shao and colleagues showed that the abrogation of PDX-1 expression in INS-1 cells downregulated GLP-1R levels, triggering a vicious circle, which might contribute to beta-cell dysfunction. These data demonstrate that PDX-1 plays a key role in GLP-1/GLP-1R pathway and in glucose-stimulated insulin synthesis, thus representing a beta-cell protective target at a nuclear level [149, 167].

7. Foxo-1

Forkhead transcription factors FOX of the O subfamily belonging to the large family of Forkhead proteins play an important role in cellular differentiation, proliferation, metabolism, and stress resistance.

FoxO1, the most predominantly expressed FoxO factor in beta-cells, is a prominent mediator of growth factor signaling, and is required to regulate both replication and response to oxidative stress in beta-cells [169, 170].

FoxO1 is normally present as a cytoplasmic phosphorylated form in healthy beta-cells; when mild hyperglycemia occurs, this factor is localized in the periphery of the nucleus. At severe hyperglycemic levels and/or oxidative stress, FoxO1 undergoes nucleoplasm translocation. Within the nucleus, it activates a transcriptional program to preserve insulin secretion, decreasing intracellular glucose metabolism with the activation of free fatty acid oxidation [165, 171, 172].

Under different conditions, FoxO1 has been shown to induce either protective or proapoptotic functions in beta-cells. FoxO1 may contribute to cellular responses against oxidative stress inducing antioxidant enzymes catalase and superoxide-dismutase and play important roles to prevent somatic mutations induced by DNA damage.

On the other hand, beta-cell exposure to oxidants results in the nuclear redistribution of FoxO1, associated with increased expression of a well-known insulin gene transcription factor, such as MafA [173].

In the pathogenesis of type 2 diabetes, FoxO1 has been shown to control beta-cell compensation of insulin resistance through cell proliferation and mass regulation. This process requires FoxO1 nuclear exclusion and is associated with increased expression of PDX-1 [169, 174].

On the other hand, FoxO1 might regulate also beta-cell mass through the integration of the proliferative and antiapoptotic signals of beta-cell growth factors. This property occurs as a result of FoxO1 inhibition through its phosphorylation-dependent nuclear exclusion. The removal of FoxO1 from the nucleus allows the expression of the main beta-cell transcription factor (such as PDX-1), which is negatively regulated by FoxO1 [175, 176].

Under chronic high glucose concentration exposure, FoxO1 has been shown to shuttle to the nucleus in a dephosphorylated form. The translocation and interaction between FoxO1 and PDX-1 represents a pivotal strategy of cellular defense to preserve the insulin synthesis that would otherwise be excessive leading to cell exhaustion.

FoxO1 might be a general regulator of beta-cell mass also in response to incretins and their analogues. Several studies reported that the GLP-1-dependent proliferation and antiapoptotic actions in beta-cell depend on FoxO1 inhibition due to its phosphorylation-dependent nuclear exclusion as a consequence of PI 3-kinase/Akt signaling cascade activation [79, 177].

In type 2 diabetes, lipotoxicity plays an essential role in inducing pancreatic beta-cell apoptotic pathways that initiate mitochondrial perturbation and increase oxidative stress [178]. Recently, it has been shown that, *in vitro* in palmitate-treated INS-1 cells, the phosphorylation of Akt and FoxO1 is decreased and the pretreatment with geniposide, a new agonist for GLP-1R, reversed this phenomenon increasing PDX-1 levels [61, 179].

FoxO1 is also an important specific transcription factor required for the maintenance of cellular identity. Recently, Talchai and coworkers demonstrated that under chronic pathophysiologic stress, beta-cells undergo dedifferentiation in nonpancreatic endocrine cells with an acquired loss of FoxO1. During metabolic stress, FoxO1 is required to limit beta-cell fate by promoting genes required for beta-cell identity and by preventing reactivation of embryonic endocrine progenitor genes. The dedifferentiation phenomenon occurs commonly in type 2 diabetes and is an ordinary mechanism of beta-cell failure in different models of metabolic stress. Beta-cell dedifferentiation is a regression to an endocrine progenitor-like stage that express markers normally observed in multipotent endocrine progenitors found within the developing pancreas [180]. Indeed, dedifferentiation is associated with an impressive upregulation of specific markers of pluripotency and cellular reprogramming, such as Neurog 3, Oct 4, Nanog, and L-Myc. These cells appeared as “degranulated” with a decreased insulin content associated to an acquired loss of FoxO1 function. However, the expression of beta-cell markers (such as PDX-1 and MafA) was preserved [172].

FoxO1 ablation seems to have little effects when insulin demand is modest. In beta-cells exposed to sustained stress, the loss of FoxO1 resulted in a profound reduction of insulin




FIGURE 1: Intracellular effects of soluble mediators are mainly mediated through the interaction with specific receptors that link extracellular signals up to modulation of gene expression. *GLP-1* signaling pathway is activated after the binding to its receptor, *GLP-1R*, and subsequent transactivation of the *EGFR*. *GLP-1*'s effects on beta-cell are mainly mediated by the *cAMP* signaling pathway. *GLP-1* potentiates glucose-induced insulin secretion, improves the function of pancreatic beta-cells by promoting neogenesis and proliferation and by decreasing apoptosis signals, increases antioxidant defense, promotes insulin gene transcription, mRNA stability, and biosynthesis, and increases the expression of *Pdx-1* and the binding of *Pdx-1* to the insulin promoter. Exendin 4, a *GLP-1R* agonist, potentiates expression of gene products subjected to the *UPR* in response to ER stress, stimulates *GK* expression, and prevents depletion of *SERCA* expression. *Metformin* enhances the expression of *GLP-1R*, via a peroxisome proliferator-activated receptor- (*PPAR*-) α -dependent mechanism, and improves the responsiveness to incretins. The *thiazolidinediones* (*TDZs*) act by activating the nuclear receptors *PPAR* γ . *TDZs* preserve pancreatic beta-cell mass and improve their function, prevent *NF- κ B* activation, improve insulin secretory capacity in patients with diabetes, protect human islets against apoptosis, and maintain the homeostasis of intracellular Ca^{2+} preventing the loss of *SERCA*. Extracellular signaling is mediated by cytosolic molecules which can be enzymes, ions, and so on. The *PI3K/Akt* signaling is a converging pathway in the regulation of beta-cell mass by growth factors, insulin, incretins, and glucose. The health of the beta-cell is also related to the maintenance of its homeostasis during its intensive function. The *UPR* restores ER homeostasis by decreasing ER protein load and increasing ER folding capacity. Intracellular Ca^{2+} concentration is important for *GSIS*, and also for ER function. The enzyme *GK*, which is considered a “glucose sensor” in pancreatic beta-cells, regulates pancreatic beta cell mass as well as their function. The temporally fluctuating activation of stress signaling is required for the maintenance of beta-cell survival, whereas its persistent activation results in beta-cell dysfunction and apoptosis. Indeed, ROS generation is not only a harmful process but, rather, plays a substantial role in the normal insulin signal transduction and is one of the metabolic signals stimulating insulin secretion. The ROS levels need to be finely regulated to keep good radicals from going bad thus avoiding oxidative damages. The ratio of the oxidized form of glutathione (*GSSG*) and the reduced form (*GSH*) is a dynamic indicator of the oxidative stress. The cellular adaptive response to oxidative stress is finely regulated by *Nrf2*, which upregulates transcription of antioxidant and phase II detoxification enzymes. Regulation of gene transcription is regulated at different biological levels. Recently, miRNAs target genes emerged important for pancreas development, beta-cell proliferation, insulin secretion, and exocytosis. Interestingly, as expression of the transcription factors implicated in the regulation of insulin transcription, such as *MafA*, *Pdx-1*, and *FoxO1*, are controlled by the relationship between themselves for instance, *FoxO1* and *PDX-1* bind directly to the *MafA* promoter and mediate *MafA* transcription, and transcription of the gene coding for *PDX-1* is negatively regulated by the binding of *FoxO1* to the *PDX-1* promoter.

producing cells due to the deconstruction of the mature beta-cell state [172].

Although these observations provide hope for the development of a treatment for beta-cell dysfunction in diabetes

based on the “redifferentiation” of the beta-cells, whether such transient states might occur during diabetogenesis, and whether beta-cell regeneration would be possible, remains to be explored.

8. Nrf2

The oxidative stress can directly or indirectly disturb physiological functions of many cellular macromolecules such as DNA, protein, and lipids and activate cellular stress-sensitive signaling pathways [130, 181]. The induction of antioxidant/detoxification enzymes (e.g., *N*-acetylcysteine and aminoguanidine, which enhance cellular ROS-scavenging capacity) represents a key element in the maintenance of cellular redox homeostasis. Among these, the Nuclear factor E2-related factor 2 (Nrf2) is considered as a master regulator of the cellular adaptive response to oxidative stress and represents a critically important cellular defense mechanism that limits oxidative damage [181].

In response to oxidative stress, Nrf2 heterodimerizes with small Maf proteins and other basic leucine zipper proteins, binding to antioxidant response elements (AREs) in the promoters of many phase II detoxification (e.g., glutathione-S-transferases and NAD[P]H quinone oxidoreductase) and antioxidant genes (e.g., heme oxygenase-1, glutathione peroxidase, Cu/Zn-superoxide dismutase (SOD), and Mn-SOD) [182, 183].

In the early stages of oxidative stress, the adaptive response, primarily regulated by Nrf2, is the main mechanism upregulating antioxidants and phase II detoxification enzymes.

In the absence of an appropriate compensatory response from the endogenous antioxidant network, the oxidative stress may cause oxidative damage and activate the cell death machinery. In this regard, the abolishment of the Nrf2-mediated antioxidant response by targeted disruption of the Nrf2 gene in beta-cells due to various stress conditions (e.g., glucose starvation, oxidative stress, hypoxia, high fat or cholesterol, aberrant levels of free fatty acid, and inflammatory cytokines) perturbed the protein homeostasis, leading to the accumulation of misfolded proteins in the ER lumen [183].

Nrf2-mediated antioxidant response has been shown to play a paradoxical role in insulin secretion. Under low environmentally levels of detrimental stimuli, beta-cells can adapt to the condition adequately by activating the Nrf2-ARE system, thus minimizing oxidative damage-related impairment of insulin secretion. Under chronic exposure conditions, the adaptively increased endogenous antioxidant capacity might interfere with glucose-dependent endogenous ROS signaling leading to an excessive and detrimental decreased in glucose-stimulated insulin secretion [181, 183].

Recently, Lee and coworkers reported that Nrf2 upregulated the proteasome catalytic subunit Psmb5, leading to a novel concept that the proteasome may participate in the cellular defense against different sources of stress [184].

Nrf2, controlling a battery of protective genes, represents an important mediator, by which mammalian cells can sense and adapt to chemical and oxidative stresses. Strategies to pharmacologically manipulate the levels and/or activity of Nrf2 may have the potential to reduce pancreatic beta-cell dysfunction and increase sensitivity to antidiabetic treatments.

9. Potential Future Targets

Several recent studies investigated the role of miRNAs in pancreatic beta-cells, suggesting the modulation of miRNA expression to be targeted in new therapies to improve diabetes. Furthermore, considering that environmental factors and nutrition might have a pivotal role in the pathogenesis of diabetes [185], epigenetic changes in response to environmental stimuli may become a pivotal research field for future investigations [185]. Current therapeutic strategies may be further potentiated by approaches targeting these “new” factors to ameliorate pancreatic beta-cell function.

10. Conclusion

The progression from glucose intolerance to type 2 diabetes is finely related with insulin secretory dysfunction and significant loss of functional beta-cells. A better understanding of the protective molecular pathways improving pancreatic beta-cell dysfunction is of primary importance to block the natural history of type 2 diabetes (Figure 1). This narrative review leads to new therapeutic targets potentially capable of preserving beta-cell function.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This research was funded by EU FP7, Grant number 201668, AtheroRemo to Dr. F. Mach. This work was also supported by the Swiss National Science Foundation Grants to Dr. F. Mach (no. 310030-118245) and Dr. F. Montecucco (no. 32003B-134963/1). This work was funded by a Grant from Novartis Foundation to Dr. F. Montecucco.

References

- [1] P. Rorsman, “The pancreatic beta-cell as a fuel sensor: an electrophysiologist’s viewpoint,” *Diabetologia*, vol. 40, no. 5, pp. 487–495, 1997.
- [2] S. E. Kahn, “Clinical review 135: the importance of β -cell failure in the development and progression of type 2 diabetes,” *Journal of Clinical Endocrinology and Metabolism*, vol. 86, no. 9, pp. 4047–4058, 2001.
- [3] Y. Lin and Z. Sun, “Current views on type 2 diabetes,” *Journal of Endocrinology*, vol. 204, no. 1, pp. 1–11, 2010.
- [4] M. Stumvoll, B. J. Goldstein, and T. W. van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” *The Lancet*, vol. 365, no. 9467, pp. 1333–1346, 2005.
- [5] P. Rorsman, L. Eliasson, E. Renström, J. Gromada, S. Barg, and S. Göpel, “The cell physiology of biphasic insulin secretion,” *News in Physiological Sciences*, vol. 15, no. 2, pp. 72–77, 2000.
- [6] D. Ross Laybutt, H. Kaneto, W. Hasenkamp et al., “Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to β -cell survival during chronic hyperglycemia,” *Diabetes*, vol. 51, no. 2, pp. 413–423, 2002.
- [7] J. C. Jonas, A. Sharma, W. Hasenkamp et al., “Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in

- an animal model of diabetes,” *Journal of Biological Chemistry*, vol. 274, no. 20, pp. 14112–14121, 1999.
- [8] Y. Tokuyama, J. Sturis, A. M. DePaoli et al., “Evolution of β -cell dysfunction in the male Zucker diabetic fatty rat,” *Diabetes*, vol. 44, no. 12, pp. 1447–1457, 1995.
 - [9] V. Poitout, J. Amyot, M. Semache, B. Zarrouki, D. Hagman, and G. Fontès, “Glucolipotoxicity of the pancreatic beta cell,” *Biochimica et Biophysica Acta*, vol. 1801, no. 3, pp. 289–298, 2010.
 - [10] V. Poitout and R. P. Robertson, “Minireview: secondary β -cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity,” *Endocrinology*, vol. 143, no. 2, pp. 339–342, 2002.
 - [11] M. Cnop, J. Vidal, R. L. Hull et al., “Progressive loss of β -cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes,” *Diabetes Care*, vol. 30, no. 3, pp. 677–682, 2007.
 - [12] R. Robertson, H. Zhou, T. Zhang, and J. S. Harmon, “Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes,” *Cell Biochemistry and Biophysics*, vol. 48, no. 2–3, pp. 139–146, 2007.
 - [13] R. P. Robertson, “ β -Cell deterioration during diabetes: what’s in the gun?” *Trends in Endocrinology and Metabolism*, vol. 20, no. 8, pp. 388–393, 2009.
 - [14] D. L. Eizirik, A. K. Cardozo, and M. Cnop, “The role for endoplasmic reticulum stress in diabetes mellitus,” *Endocrine Reviews*, vol. 29, no. 1, pp. 42–61, 2008.
 - [15] W. Inaba, H. Mizukami, K. Kamata, K. Takahashi, K. Tsuboi, and S. Yagihashi, “Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats,” *European Journal of Pharmacology*, vol. 691, no. 1–3, pp. 297–306, 2012.
 - [16] J. A. Pospisilik, J. Martin, T. Doty et al., “Dipeptidyl peptidase IV inhibitor treatment stimulates β -cell survival and islet neogenesis in streptozotocin-induced diabetic rats,” *Diabetes*, vol. 52, no. 3, pp. 741–750, 2003.
 - [17] M. K. Reimer, J. J. Holst, and B. Åhrén, “Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice,” *European Journal of Endocrinology*, vol. 146, no. 5, pp. 717–727, 2002.
 - [18] Q. Wang and P. Brubaker, “Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice,” *Diabetologia*, vol. 45, no. 9, pp. 1263–1273, 2002.
 - [19] C. Tourrel, D. Bailbe, M. Lacorne, M. J. Meile, M. Kergoat, and B. Portha, “Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β -cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4,” *Diabetes*, vol. 51, no. 5, pp. 1443–1452, 2002.
 - [20] R. Perfetti, J. I. E. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 induces cell proliferation and increases pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats,” *Endocrinology*, vol. 141, no. 12, pp. 4600–4605, 2000.
 - [21] L. Farilla, H. Hongxiang, C. Bertolotto et al., “Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats,” *Endocrinology*, vol. 143, no. 11, pp. 4397–4408, 2002.
 - [22] B. Thorens, “Expression cloning of the pancreatic β cell receptor for the gluco- incretin hormone glucagon-like peptide 1,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 18, pp. 8641–8645, 1992.
 - [23] P. L. Brubaker and D. J. Drucker, “Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system,” *Endocrinology*, vol. 145, no. 6, pp. 2653–2659, 2004.
 - [24] A. Haq, K. Sheth, M. Abdullatif, F. A. A. Jabbar, C. Hamilton, and S. Al-Sedairy, “Suppression/stimulation of chemiluminescence by human seminal plasma,” *Clinica Chimica Acta*, vol. 200, no. 1, pp. 67–69, 1991.
 - [25] D. J. Drucker, “Glucagon-Like Peptide-1 and the Islet β -Cell: augmentation of Cell Proliferation and Inhibition of Apoptosis,” *Endocrinology*, vol. 144, no. 12, pp. 5145–5148, 2003.
 - [26] X. Wang, J. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β -cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism,” *Endocrinology*, vol. 142, no. 5, pp. 1820–1827, 2001.
 - [27] M. A. Hussain, D. L. Porras, M. H. Rowe et al., “Increased pancreatic β -cell proliferation mediated by CREB binding protein gene activation,” *Molecular and Cellular Biology*, vol. 26, no. 20, pp. 7747–7759, 2006.
 - [28] D. A. Stoffers, T. J. Kieffer, M. A. Hussain et al., “Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas,” *Diabetes*, vol. 49, no. 5, pp. 741–748, 2000.
 - [29] J. Buteau, W. El-Assaad, C. J. Rhodes, L. Mosenberg, E. Joly, and M. Prentki, “Glucagon-like peptide-1 prevents beta cell glucolipotoxicity,” *Diabetologia*, vol. 47, no. 5, pp. 806–815, 2004.
 - [30] A. Puddu, D. Storace, A. Durante, P. Odetti, and G. L. Viviani, “Glucagon-like peptide-1 counteracts the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T 15,” *Biochemical and Biophysical Research Communications*, vol. 398, no. 3, pp. 462–466, 2010.
 - [31] A. M. Lambeir, C. Durinx, S. Scharpé, and I. De Meester, “Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV,” *Critical Reviews in Clinical Laboratory Sciences*, vol. 40, no. 3, pp. 209–294, 2003.
 - [32] L. K. Phillips and J. B. Prins, “Update on incretin hormones,” *Annals of the New York Academy of Sciences*, vol. 1243, pp. E55–E74, 2011.
 - [33] F. K. Knop, T. Vilsbøll, and J. J. Holst, “Incretin-based therapy of type 2 diabetes mellitus,” *Current Protein and Peptide Science*, vol. 10, no. 1, pp. 46–55, 2009.
 - [34] T. Vilsbøll and F. K. Knop, “Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus,” *BioDrugs*, vol. 22, no. 4, pp. 251–257, 2008.
 - [35] E. J. Verspohl, “Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors,” *Pharmacology and Therapeutics*, vol. 124, no. 1, pp. 113–138, 2009.
 - [36] S. A. Ross and J. M. Ekoé, “Incretin agents in type 2 diabetes,” *Canadian Family Physician*, vol. 56, no. 7, pp. 639–648, 2010.
 - [37] Y. M. Cho and T. J. Kieffer, “New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitizer,” *Diabetologia*, vol. 54, no. 2, pp. 219–222, 2011.
 - [38] G. G. Graham, J. Punt, M. Arora et al., “Clinical pharmacokinetics of metformin,” *Clinical Pharmacokinetics*, vol. 50, no. 2, pp. 81–98, 2011.
 - [39] M. L. Reitman and E. E. Schadt, “Pharmacogenetics of metformin response: a step in the path toward personalized medicine,” *Journal of Clinical Investigation*, vol. 117, no. 5, pp. 1226–1229, 2007.

- [40] G. Zhou, R. Myers, Y. Li et al., "Role of AMP-activated protein kinase in mechanism of metformin action," *Journal of Clinical Investigation*, vol. 108, no. 8, pp. 1167–1174, 2001.
- [41] M. R. Owen, E. Doran, and A. P. Halestrap, "Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain," *Biochemical Journal*, vol. 348, no. 3, pp. 607–614, 2000.
- [42] M. Y. El-Mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, and X. Leverve, "Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I," *Journal of Biological Chemistry*, vol. 275, no. 1, pp. 223–228, 2000.
- [43] A. Maida, B. J. Lamont, X. Cao, and D. J. Drucker, "Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor- α in mice," *Diabetologia*, vol. 54, no. 2, pp. 339–349, 2011.
- [44] G. Patané, S. Piro, A. M. Rabuazzo, M. Anello, R. Vigneri, and F. Purrello, "Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic β -cells," *Diabetes*, vol. 49, no. 5, pp. 735–740, 2000.
- [45] P. Marchetti, S. Del Guerra, L. Marselli et al., "Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin," *Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 11, pp. 5535–5541, 2004.
- [46] I. Leclerc, W. W. Woltersdorf, G. Da Silva Xavier et al., "Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion," *The American Journal of Physiology*, vol. 286, no. 6, pp. E1023–E1031, 2004.
- [47] B. A. Kefas, Y. Cai, K. Kerckhofs et al., "Metformin-induced stimulation of AMP-activated protein kinase in β -cells impairs their glucose responsiveness and can lead to apoptosis," *Biochemical Pharmacology*, vol. 68, no. 3, pp. 409–416, 2004.
- [48] C. F. Sum, J. M. Webster, A. B. Johnson, C. Catalano, B. G. Cooper, and R. Taylor, "The effect of intravenous metformin on glucose metabolism during hyperglycaemia in Type 2 diabetes," *Diabetic Medicine*, vol. 9, no. 1, pp. 61–65, 1992.
- [49] C. Wilcock and C. J. Bailey, "Accumulation of metformin by tissues of the normal and diabetic mouse," *Xenobiotica*, vol. 24, no. 1, pp. 49–57, 1994.
- [50] B. M. Spiegelman, "PPAR- γ : adipogenic regulator and thiazolidinedione receptor," *Diabetes*, vol. 47, no. 4, pp. 507–514, 1998.
- [51] D. S. Bell, "Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus," *Postgraduate Medicine*, Spec No, pp. 35–44, 2003.
- [52] I. W. Campbell and S. Mariz, " β -Cell preservation with thiazolidinediones," *Diabetes Research and Clinical Practice*, vol. 76, no. 2, pp. 163–176, 2007.
- [53] C. Ao, Y. Huo, L. Qi, Z. Xiong, L. Xue, and Y. Qi, "Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF- κ B," *Cell Biology International*, vol. 34, no. 7, pp. 723–730, 2010.
- [54] X. Liu, D. Luo, M. Zheng, Y. Hao, L. Hou, and S. Zhang, "Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF κ B activation," *European Journal of Pharmacology*, vol. 629, no. 1–3, pp. 153–158, 2010.
- [55] Y. Saitoh, C. Chun-ping, K. Noma, H. Ueno, M. Mizuta, and M. Nakazato, "Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic β -cells," *Diabetes, Obesity and Metabolism*, vol. 10, no. 7, pp. 564–573, 2008.
- [56] A. R. Diani, G. Sawada, B. Wyse, F. T. Murray, and M. Khan, "Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes," *The American Journal of Physiology*, vol. 286, no. 1, pp. E116–E122, 2004.
- [57] Y. Miyazaki and R. A. Defronzo, "Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients," *Diabetes, Obesity and Metabolism*, vol. 10, no. 12, pp. 1204–1211, 2008.
- [58] E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban, "Pioglitazone and sodium salicylate protect human β -cells against apoptosis and impaired function induced by glucose and interleukin-1 β ," *Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 10, pp. 5059–5066, 2004.
- [59] F. Kawasaki, M. Matsuda, Y. Kanda, H. Inoue, and K. Kaku, "Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice," *The American Journal of Physiology*, vol. 288, no. 3, pp. E510–E518, 2005.
- [60] H. Ishida, M. Takizawa, S. Ozawa et al., "Pioglitazone improves insulin secretory capacity and prevents the loss of β -cell mass in obese diabetic db/db mice: possible protection of β cells from oxidative stress," *Metabolism*, vol. 53, no. 4, pp. 488–494, 2004.
- [61] C. Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler, "Activation of peroxisome proliferator-activated receptor- γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3 γ -kinase-dependent pathway," *Journal of Clinical Endocrinology and Metabolism*, vol. 90, no. 12, pp. 6678–6686, 2005.
- [62] T. Kono, G. Ahn, D. R. Moss et al., "PPAR- γ activation restores pancreatic islet SERCA2 levels and prevents β -cell dysfunction under conditions of hyperglycemic and cytokine stress," *Molecular Endocrinology*, vol. 26, no. 2, pp. 257–271, 2012.
- [63] A. Puddu, R. Sanguineti, A. Durante, and G. L. Viviani, "Pioglitazone attenuates the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T15," *Regulatory Peptides*, vol. 177, no. 1–3, pp. 79–84, 2012.
- [64] A. D. Kohn, K. S. Kovacina, and R. A. Roth, "Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase," *EMBO Journal*, vol. 14, no. 17, pp. 4288–4295, 1995.
- [65] T. F. Franke, "Intracellular signaling by Akt: bound to be specific," *Science Signaling*, vol. 1, no. 24, p. pe29, 2008.
- [66] E. Bernal-Mizrachi, W. Wen, S. Stahlhut, C. M. Welling, and M. A. Permutt, "Islet β cell expression of constitutively active Akt1/PKB α induces striking hypertrophy, hyperplasia, and hyperinsulinemia," *Journal of Clinical Investigation*, vol. 108, no. 11, pp. 1631–1638, 2001.
- [67] R. L. Tuttle, N. S. Gill, W. Pugh et al., "Regulation of pancreatic β -cell growth and survival by the serine/threonine protein kinase Akt1/PKB α ," *Nature Medicine*, vol. 7, no. 10, pp. 1133–1137, 2001.
- [68] E. Bernal-Mizrachi, S. Fatrai, J. D. Johnson et al., "Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells," *Journal of Clinical Investigation*, vol. 114, no. 7, pp. 928–936, 2004.
- [69] M. Kasuga, "Insulin resistance and pancreatic β cell failure," *Journal of Clinical Investigation*, vol. 116, no. 7, pp. 1756–1760, 2006.

- [70] Y. Dor, J. Brown, O. I. Martinez, and D. A. Melton, "Adult pancreatic β -cells are formed by self-duplication rather than stem-cell differentiation," *Nature*, vol. 429, no. 6987, pp. 41–46, 2004.
- [71] S. Georgia and A. Bhushan, " β cell replication is the primary mechanism for maintaining postnatal β cell mass," *Journal of Clinical Investigation*, vol. 114, no. 7, pp. 963–968, 2004.
- [72] J. A. Kushner, M. A. Ciemerych, E. Sicinska et al., "Cyclins D2 and D1 are essential for postnatal pancreatic β -cell growth," *Molecular and Cellular Biology*, vol. 25, no. 9, pp. 3752–3762, 2005.
- [73] S. Fatrai, L. Elghazi, N. Balcazar et al., "Akt induces β -cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity," *Diabetes*, vol. 55, no. 2, pp. 318–325, 2006.
- [74] D. J. Burks and M. F. White, "IRS proteins and beta-cell function," *Diabetes*, vol. 50, supplement 1, pp. S140–S145, 2001.
- [75] L. Elghazi and E. Bernal-Mizrachi, "Akt and PTEN: β -cell mass and pancreas plasticity," *Trends in Endocrinology and Metabolism*, vol. 20, no. 5, pp. 243–251, 2009.
- [76] Z. Liu and J. F. Habener, "Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation," *Journal of Biological Chemistry*, vol. 283, no. 13, pp. 8723–8735, 2008.
- [77] Q. Wang, L. Li, E. Xu, V. Wong, C. Rhodes, and P. L. Brubaker, "Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells," *Diabetologia*, vol. 47, no. 3, pp. 478–487, 2004.
- [78] J. Buteau, S. Foisy, E. Joly, and M. Prentki, "Glucagon-like peptide 1 induces pancreatic β -cell proliferation via transactivation of the epidermal growth factor receptor," *Diabetes*, vol. 52, no. 1, pp. 124–132, 2003.
- [79] J. Buteau, M. L. Spatz, and D. Accili, "Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β -cell mass," *Diabetes*, vol. 55, no. 5, pp. 1190–1196, 2006.
- [80] U. S. Jhala, G. Canettieri, R. A. Screaton et al., "cAMP promotes pancreatic β -cell survival via CREB-mediated induction of IRS2," *Genes and Development*, vol. 17, no. 13, pp. 1575–1580, 2003.
- [81] S. Srinivasan, E. Bernal-Mizrachi, M. Ohsugi, and M. A. Permutt, "Glucose promotes pancreatic islet β -cell survival through a PI 3-kinase/Akt-signaling pathway," *The American Journal of Physiology*, vol. 283, no. 4, pp. E784–E793, 2002.
- [82] L. M. Dickson and C. J. Rhodes, "Pancreatic β -cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt?" *The American Journal of Physiology*, vol. 287, no. 2, pp. E192–E198, 2004.
- [83] C. E. Wrede, L. M. Dickson, M. K. Lingohr, I. Briaud, and C. J. Rhodes, "Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic β -cells (INS-1)," *Journal of Biological Chemistry*, vol. 277, no. 51, pp. 49676–49684, 2002.
- [84] T. A. Buchanan, A. H. Xiang, R. K. Peters et al., "Preservation of pancreatic β -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women," *Diabetes*, vol. 51, no. 9, pp. 2796–2803, 2002.
- [85] F. Ovalle and D. S. H. Bell, "Effect of rosiglitazone versus insulin on the pancreatic β -cell function of subjects with type 2 diabetes," *Diabetes Care*, vol. 27, no. 11, pp. 2585–2589, 2004.
- [86] C. J. Rhodes, "Type 2 diabetes: a matter of β -cell life and death?" *Science*, vol. 307, no. 5708, pp. 380–384, 2005.
- [87] D. Ron and P. Walter, "Signal integration in the endoplasmic reticulum unfolded protein response," *Nature Reviews Molecular Cell Biology*, vol. 8, no. 7, pp. 519–529, 2007.
- [88] D. T. Rutkowski and R. J. Kaufman, "A trip to the ER: coping with stress," *Trends in Cell Biology*, vol. 14, no. 1, pp. 20–28, 2004.
- [89] D. Ron, "Translational control in the endoplasmic reticulum stress response," *Journal of Clinical Investigation*, vol. 110, no. 10, pp. 1383–1388, 2002.
- [90] R. C. Wek, H. Y. Jiang, and T. G. Anthony, "Coping with stress: eIF2 kinases and translational control," *Biochemical Society Transactions*, vol. 34, pp. 7–11, 2006.
- [91] J. Wu and R. J. Kaufman, "From acute ER stress to physiological roles of the unfolded protein response," *Cell Death and Differentiation*, vol. 13, no. 3, pp. 374–384, 2006.
- [92] L. Zhang, E. Lai, T. Teodoro, and A. Volchuk, "GRP78, but not protein-disulfide isomerase, partially reverses hyperglycemia-induced inhibition of insulin synthesis and secretion in pancreatic β -cells," *Journal of Biological Chemistry*, vol. 284, no. 8, pp. 5289–5298, 2009.
- [93] M. Wang, X. R. Zhao, P. Wang et al., "Glucose regulated proteins 78 protects insulinoma cells (NIT-1) from death induced by streptozotocin, cytokines or cytotoxic T lymphocytes," *International Journal of Biochemistry and Cell Biology*, vol. 39, no. 11, pp. 2076–2082, 2007.
- [94] T. Gotoh, K. Terada, S. Oyadomari, and M. Mori, "hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria," *Cell Death and Differentiation*, vol. 11, no. 4, pp. 390–402, 2004.
- [95] M. Cnop, L. Ladrière, M. Igoillo-Esteve, R. F. Moura, and D. A. Cunha, "Causes and cures for endoplasmic reticulum stress in lipotoxic β -cell dysfunction," *Diabetes, Obesity and Metabolism*, vol. 12, supplement 2, pp. 76–82, 2010.
- [96] S. E. Choi, Y. J. Lee, H. J. Jang et al., "A chemical chaperone 4-PBA ameliorates palmitate-induced inhibition of glucose-stimulated insulin secretion (GSIS)," *Archives of Biochemistry and Biophysics*, vol. 475, no. 2, pp. 109–114, 2008.
- [97] D. A. Cunha, L. Ladrière, F. Ortis et al., "Glucagon-like peptide-1 agonists protect pancreatic β -cells from lipotoxic endoplasmic reticulum stress through upregulation of BIP and JunB," *Diabetes*, vol. 58, no. 12, pp. 2851–2862, 2009.
- [98] B. Yusta, L. L. Baggio, J. L. Estall et al., "GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress," *Cell Metabolism*, vol. 4, no. 5, pp. 391–406, 2006.
- [99] G. Drews, P. Krippeit-Drews, and M. Dufer, "Electrophysiology of islet cells," *Advances in Experimental Medicine and Biology*, vol. 654, pp. 115–163, 2010.
- [100] J. Lang, "Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion," *European Journal of Biochemistry*, vol. 259, no. 1-2, pp. 3–17, 1999.
- [101] H. F. Lodish and N. Kong, "Perturbation of cellular calcium blocks exit of secretory proteins from the rough endoplasmic reticulum," *Journal of Biological Chemistry*, vol. 265, no. 19, pp. 10893–10899, 1990.
- [102] F. Pena, A. Jansens, G. Van Zadelhoff, and I. Braakman, "Calcium as a crucial cofactor for low density lipoprotein receptor folding in the endoplasmic reticulum," *Journal of Biological Chemistry*, vol. 285, no. 12, pp. 8656–8664, 2010.
- [103] A. Hovnanian, "SERCA pumps and human diseases," *Sub-Cellular Biochemistry*, vol. 45, pp. 337–363, 2007.

- [104] C. E. Moore, O. Omikorede, E. Gomez, G. B. Willars, and T. P. Herbert, "PERK activation at low glucose concentration is mediated by SERCA pump inhibition and confers preemptive cytoprotection to pancreatic β -cells," *Molecular Endocrinology*, vol. 25, no. 2, pp. 315–326, 2011.
- [105] A. K. Cardozo, F. Ortis, J. Storling et al., "Cytokines downregulate the sarcoendoplasmic reticulum pump Ca^{2+} ATPase 2b and deplete endoplasmic reticulum Ca^{2+} , leading to induction of endoplasmic reticulum stress in pancreatic β -cells," *Diabetes*, vol. 54, no. 2, pp. 452–461, 2005.
- [106] C. Evans-Molina, R. D. Robbins, T. Kono et al., "Peroxisome proliferator-activated receptor γ activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure," *Molecular and Cellular Biology*, vol. 29, no. 8, pp. 2053–2067, 2009.
- [107] M. W. Roe, L. H. Philipson, C. J. Frangakis et al., "Defective glucose-dependent endoplasmic reticulum Ca^{2+} sequestration in diabetic mouse islets of Langerhans," *Journal of Biological Chemistry*, vol. 269, no. 28, pp. 18279–18282, 1994.
- [108] J. Y. Kim, D. M. Lim, H. S. Park et al., "Exendin-4 protects against sulfonylurea-induced β -cell apoptosis," *Journal of Pharmacological Sciences*, vol. 118, no. 1, pp. 65–74, 2012.
- [109] F. M. Matschinsky, "Glucokinase as glucose sensor and metabolic signal generator in pancreatic β -cells and hepatocytes," *Diabetes*, vol. 39, no. 6, pp. 647–652, 1990.
- [110] B. Glaser, P. Kesavan, M. Heyman et al., "Familial hyperinsulinism caused by an activating glucokinase mutation," *The New England Journal of Medicine*, vol. 338, no. 4, pp. 226–230, 1998.
- [111] G. Velho, P. Froguel, K. Clement et al., "Primary pancreatic β -cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young," *The Lancet*, vol. 340, no. 8817, pp. 444–448, 1992.
- [112] Y. Terauchi, I. Takamoto, N. Kubota et al., "Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance," *Journal of Clinical Investigation*, vol. 117, no. 1, pp. 246–257, 2007.
- [113] Y. Kajimoto, T. Matsuoka, H. Kaneto et al., "Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells," *Diabetologia*, vol. 42, no. 12, pp. 1417–1424, 1999.
- [114] F. M. Matschinsky, "Assessing the potential of glucokinase activators in diabetes therapy," *Nature Reviews Drug Discovery*, vol. 8, no. 5, pp. 399–416, 2009.
- [115] S. Y. Ding, A. Nkobena, C. A. Kraft, M. L. Markwardt, and M. A. Rizzo, "Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic β cells," *Journal of Biological Chemistry*, vol. 286, no. 19, pp. 16768–16774, 2011.
- [116] K. Murao, J. Li, H. Imachi et al., "Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic β -cell line," *Diabetes, Obesity and Metabolism*, vol. 11, no. 10, pp. 939–946, 2009.
- [117] M. Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, "Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells," *Diabetes*, vol. 46, no. 11, pp. 1733–1742, 1997.
- [118] J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky, "Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes," *Endocrine Reviews*, vol. 23, no. 5, pp. 599–622, 2002.
- [119] M. A. Gonzalez-Moles, I. Ruiz-Avila, A. Rodriguez-Archilla et al., "Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays," *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, vol. 95, no. 6, pp. 688–692, 2003.
- [120] R. P. Robertson, J. Harmon, P. O. Tran, Y. Tanaka, and H. Takahashi, "Glucose toxicity in β -cells: type 2 diabetes, good radicals gone bad, and the glutathione connection," *Diabetes*, vol. 52, no. 3, pp. 581–587, 2003.
- [121] S. G. Rhee, K. S. Yang, S. W. Kang, H. A. Woo, and T. S. Chang, "Controlled elimination of intracellular H_2O_2 : regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification," *Antioxidants and Redox Signaling*, vol. 7, no. 5–6, pp. 619–626, 2005.
- [122] J. Pi, W. Qu, J. M. Reece, Y. Kumagai, and M. P. Waalkes, "Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide," *Experimental Cell Research*, vol. 290, no. 2, pp. 234–245, 2003.
- [123] T. Nguyen, P. J. Sherratt, and C. B. Pickett, "Regulatory mechanisms controlling gene expression mediated by the antioxidant response element," *Annual Review of Pharmacology and Toxicology*, vol. 43, pp. 233–260, 2003.
- [124] X. Wang and C. X. Hai, "ROS acts as a double-edged sword in the pathogenesis of type 2 diabetes mellitus: is Nrf2 a potential target for the treatment?" *Mini-Reviews in Medicinal Chemistry*, vol. 11, no. 12, pp. 1082–1092, 2011.
- [125] F. Q. Schafer and G. R. Buettner, "Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple," *Free Radical Biology and Medicine*, vol. 30, no. 11, pp. 1191–1212, 2001.
- [126] S. Numazawa, H. Sakaguchi, R. Aoki, T. Taira, and T. Yoshida, "Regulation of the susceptibility to oxidative stress by cysteine availability in pancreatic β -cells," *The American Journal of Physiology*, vol. 295, no. 2, pp. C468–C474, 2008.
- [127] G. A. Martens, Y. Cai, S. Hinke, G. Stangé, M. Van De Casteele, and D. Pipeleers, "Glucose suppresses superoxide generation in metabolically responsive pancreatic β cells," *Journal of Biological Chemistry*, vol. 280, no. 21, pp. 20389–20396, 2005.
- [128] Y. Tanaka, P. O. T. Tran, J. Harmon, and R. P. Robertson, "A role for glutathione peroxidase in protecting pancreatic β cells against oxidative stress in a model of glucose toxicity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 19, pp. 12363–12368, 2002.
- [129] V. P. Bindokas, A. Kuznetsov, S. Sreenan, K. S. Polonsky, M. W. Roe, and L. H. Philipson, "Visualizing superoxide production in normal and diabetic rat islets of Langerhans," *Journal of Biological Chemistry*, vol. 278, no. 11, pp. 9796–9801, 2003.
- [130] J. Pi, Y. Bai, Q. Zhang et al., "Reactive oxygen species as a signal in glucose-stimulated insulin secretion," *Diabetes*, vol. 56, no. 7, pp. 1783–1791, 2007.
- [131] S. Lortz, E. Gurgul-Convey, O. Naujok, and S. Lenzen, "Overexpression of the antioxidant enzyme catalase does not interfere with the glucose responsiveness of insulin-secreting INS-1E cells and rat islets," *Diabetologia*, vol. 56, pp. 774–782, 2013.
- [132] C. Leloup, C. Turrel-Cuzin, C. Magnan et al., "Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion," *Diabetes*, vol. 58, no. 3, pp. 673–681, 2009.
- [133] M. Lagos-Quintana, R. Rauhut, W. Lendeckel, and T. Tuschl, "Identification of novel genes coding for small expressed RNAs," *Science*, vol. 294, no. 5543, pp. 853–858, 2001.
- [134] N. C. Lau, L. P. Lim, E. G. Weinstein, and D. P. Bartel, "An abundant class of tiny RNAs with probable regulatory roles in

- Caenorhabditis elegans," *Science*, vol. 294, no. 5543, pp. 858–862, 2001.
- [135] R. C. Lee and V. Ambros, "An extensive class of small RNAs in *Caenorhabditis elegans*," *Science*, vol. 294, no. 5543, pp. 862–864, 2001.
- [136] O. Dumortier and E. Van Obberghen, "MicroRNAs in pancreas development," *Diabetes, Obesity and Metabolism*, vol. 14, supplement 3, pp. 22–28.
- [137] M. V. Joglekar, V. M. Joglekar, and A. A. Hardikar, "Expression of islet-specific microRNAs during human pancreatic development," *Gene Expression Patterns*, vol. 9, no. 2, pp. 109–113, 2009.
- [138] W. P. Kloosterman, A. K. Lagendijk, R. F. Ketting, J. D. Moulton, and R. H. Plasterk, "Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development," *PLoS Biology*, vol. 5, no. 8, p. e203, 2007.
- [139] T. Melkman-Zehavi, R. Oren, S. Kredon-Russo et al., "miRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors," *EMBO Journal*, vol. 30, pp. 835–845, 2011.
- [140] V. Plaisance, A. Abderrahmani, V. Perret-Menoud, P. Jacquemin, F. Lemaigre, and R. Regazzi, "MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells," *Journal of Biological Chemistry*, vol. 281, no. 37, pp. 26932–26942, 2006.
- [141] D. Ramachandran, U. Roy, S. Garg, S. Ghosh, S. Pathak, and U. Kolthur-Seetharam, "Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic β -islets," *FEBS Journal*, vol. 278, no. 7, pp. 1167–1174, 2011.
- [142] X. Zhao, R. Mohan, S. Ozcan, and X. Tang, "MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 (MAP4K4) in pancreatic beta-cells," *Journal of Biological Chemistry*, vol. 287, pp. 31155–31164, 2012.
- [143] V. Bravo-Egana, S. Rosero, D. Klein et al., "Inflammation-mediated regulation of MicroRNA expression in transplanted pancreatic islets," *Journal of Transplantation*, vol. 2012, Article ID 723614, 15 pages, 2012.
- [144] D. M. Keller, E. A. Clark, and R. H. Goodman, "Regulation of microRNA-375 by cAMP in pancreatic beta-cells," *Molecular Endocrinology*, vol. 26, pp. 989–999, 2012.
- [145] E. Roggli, S. Gattesco, D. Caille et al., "Changes in microRNA expression contribute to pancreatic beta-cell dysfunction in prediabetic NOD mice," *Diabetes*, vol. 61, pp. 1742–1751, 2012.
- [146] N. Wijesekara, L. H. Zhang, M. H. Kang et al., "miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets," *Diabetes*, vol. 61, pp. 653–658, 2012.
- [147] S. S. Andrali, M. L. Smapley, N. L. Vanderford, and S. Özcan, "Glucose regulation of insulin gene expression in pancreatic β -cells," *Biochemical Journal*, vol. 415, no. 1, pp. 1–10, 2008.
- [148] K. Ohneda, H. Ee, and M. German, "Regulation of insulin gene transcription," *Seminars in Cell and Developmental Biology*, vol. 11, no. 4, pp. 227–233, 2000.
- [149] S. Shao, Z. Fang, X. Yu, and M. Zhang, "Transcription factors involved in glucose-stimulated insulin secretion of pancreatic beta cells," *Biochemical and Biophysical Research Communications*, vol. 384, no. 4, pp. 401–404, 2009.
- [150] S. E. Samaras, L. Zhao, A. Means, E. Henderson, T. A. Matsuoka, and R. Stein, "The islet β cell-enriched RIPE3b1/Maf transcription factor regulates pdx-1 expression," *Journal of Biological Chemistry*, vol. 278, no. 14, pp. 12263–12270, 2003.
- [151] H. Wang, T. Brun, K. Kataoka, A. J. Sharma, and C. B. Wollheim, "MAFA controls genes implicated in insulin biosynthesis and secretion," *Diabetologia*, vol. 50, no. 2, pp. 348–358, 2007.
- [152] H. Kaneto, T. Miyatsuka, D. Kawamori et al., "PDX-1 and MafA play a crucial role in pancreatic β -cell differentiation and maintenance of mature β -cell function," *Endocrine Journal*, vol. 55, no. 2, pp. 235–252, 2008.
- [153] C. Zhang, T. Moriguchi, M. Kajihara et al., "MafA is a key regulator of glucose-stimulated insulin secretion," *Molecular and Cellular Biology*, vol. 25, no. 12, pp. 4969–4976, 2005.
- [154] D. K. Hagman, L. B. Hays, S. D. Parazzoli, and V. Poitout, "Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans," *Journal of Biological Chemistry*, vol. 280, no. 37, pp. 32413–32418, 2005.
- [155] V. Poitout, D. Hagman, R. Stein, I. Artner, R. P. Robertson, and J. S. Harmon, "Regulation of the insulin gene by glucose and fatty acids," *Journal of Nutrition*, vol. 136, no. 4, pp. 873–876, 2006.
- [156] L. J. Elrick and K. Docherty, "Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1," *Diabetes*, vol. 50, no. 10, pp. 2244–2252, 2001.
- [157] W. M. Macfarlane, C. M. McKinnon, Z. A. Felton-Edkins, H. Cragg, R. F. L. James, and K. Docherty, "Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic β -cells," *Journal of Biological Chemistry*, vol. 274, no. 2, pp. 1011–1016, 1999.
- [158] T. Shu, Y. Zhu, H. Wang, Y. Lin, Z. Ma, and X. Han, "Ages decrease insulin synthesis in pancreatic β -cell by repressing pdx-1 protein expression at the post-translational level," *PLoS ONE*, vol. 6, no. 4, Article ID e18782, 2011.
- [159] M. Alikhani, C. M. MacLellan, M. Raptis, S. Vora, P. C. Trackman, and D. T. Graves, "Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor," *The American Journal of Physiology*, vol. 292, no. 2, pp. C850–C856, 2007.
- [160] R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt, "Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation," *Glycobiology*, vol. 15, no. 7, pp. 16R–28R, 2005.
- [161] Y. Saisho, T. Maruyama, H. Hirose, and T. Saruta, "Relationship between proinsulin-to-insulin ratio and advanced glycation endproducts in Japanese type 2 diabetic subjects," *Diabetes Research and Clinical Practice*, vol. 78, no. 2, pp. 182–188, 2007.
- [162] H. Vlassara and M. R. Palace, "Diabetes and advanced glycation endproducts," *Journal of Internal Medicine*, vol. 251, no. 2, pp. 87–101, 2002.
- [163] D. Kawamori, Y. Kajimoto, H. Kaneto et al., "Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH₂-terminal kinase," *Diabetes*, vol. 52, no. 12, pp. 2896–2904, 2003.
- [164] A. P. Robertson, "Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes," *Journal of Biological Chemistry*, vol. 279, no. 41, pp. 42351–42354, 2004.
- [165] A. Puddu, D. Storace, P. Odetti, and G. L. Viviani, "Advanced glycation end-products affect transcription factors regulating insulin gene expression," *Biochemical and Biophysical Research Communications*, vol. 395, no. 1, pp. 122–125, 2010.
- [166] Y. Gao, J. I. Miyazaki, and G. W. Hart, "The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its

- DNA binding activity and insulin secretion in min6 β -cells," *Archives of Biochemistry and Biophysics*, vol. 415, no. 2, pp. 155–163, 2003.
- [167] E. Bonora, "Protection of pancreatic beta-cells: is it feasible?" *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 18, no. 1, pp. 74–83, 2008.
- [168] J. Buteau, R. Roduit, S. Susini, and M. Prentki, "Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)- cells," *Diabetologia*, vol. 42, no. 7, pp. 856–864, 1999.
- [169] H. Okamoto, M. L. Hribal, H. V. Lin, W. R. Bennett, A. Ward, and D. Accili, "Role of the forkhead protein FoxO1 in β cell compensation to insulin resistance," *Journal of Clinical Investigation*, vol. 116, no. 3, pp. 775–782, 2006.
- [170] D. A. Glauser and W. Schlegel, "The emerging role of FOXO transcription factors in pancreatic β cells," *Journal of Endocrinology*, vol. 193, no. 2, pp. 195–207, 2007.
- [171] J. Buteau, A. Shlien, S. Foisy, and D. Accili, "Metabolic diapause in pancreatic β -cells expressing a gain-of-function mutant of the forkhead protein Foxo1," *Journal of Biological Chemistry*, vol. 282, no. 1, pp. 287–293, 2007.
- [172] C. Talchai, S. Xuan, H. V. Lin, L. Sussel, and D. Accili, "Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure," *Cell*, vol. 150, pp. 1223–1234, 2012.
- [173] T. Kitamura and Y. Ido Kitamura, "Role of FoxO proteins in pancreatic β cells," *Endocrine Journal*, vol. 54, no. 4, pp. 507–515, 2007.
- [174] J. Nakae, W. H. Biggs III, T. Kitamura et al., "Regulation of insulin action and pancreatic β -cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1," *Nature Genetics*, vol. 32, no. 2, pp. 245–253, 2002.
- [175] D. Kawamori, H. Kaneto, Y. Nakatani et al., "The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation," *Journal of Biological Chemistry*, vol. 281, no. 2, pp. 1091–1098, 2006.
- [176] P. S. Corbet and D. D. Chadee, "The diel pattern of entry to outdoor oviposition sites by female *Aedes aegypti* (L.) (Diptera: Culicidae) that then laid eggs there: a preliminary study," *Annals of Tropical Medicine and Parasitology*, vol. 86, no. 5, pp. 523–528, 1992.
- [177] D. Fang, Z. Huang, H. Guan et al., "The Akt/FoxO1/p27 pathway mediates the proliferative action of liraglutide in beta cells," *Molecular Medicine Reports*, vol. 5, pp. 233–238, 2012.
- [178] E. Lai, G. Bikopoulos, M. B. Wheeler, M. Rozakis-Adcock, and A. Volchuk, "Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic β -cells," *The American Journal of Physiology*, vol. 294, no. 3, pp. E540–E550, 2008.
- [179] C. F. Deacon, "Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors," *Diabetes, Obesity and Metabolism*, vol. 9, supplement 1, pp. 23–31, 2007.
- [180] S. Puri and M. Hebrok, "Diabetic beta cells: to be or not to be?" *Cell*, vol. 150, pp. 1103–1104, 2012.
- [181] J. Pi, Q. Zhang, J. Fu et al., "ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function," *Toxicology and Applied Pharmacology*, vol. 244, no. 1, pp. 77–83, 2010.
- [182] J. Maher and M. Yamamoto, "The rise of antioxidant signaling—The evolution and hormetic actions of Nrf2," *Toxicology and Applied Pharmacology*, vol. 244, no. 1, pp. 4–15, 2010.
- [183] B. Yang, J. Fu, H. Zheng et al., "Deficiency in the nuclear factor E2-related factor 2 renders pancreatic beta-cells vulnerable to arsenic-induced cell damage," *Toxicology and Applied Pharmacology*, vol. 264, pp. 315–323, 2012.
- [184] S. Lee, E. G. Hur, I. G. Ryoo, K. A. Jung, J. Kwak, and M. K. Kwak, "Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic beta-cells," *Toxicology and Applied Pharmacology*, vol. 264, pp. 431–438, 2012.
- [185] E. R. Gilbert and D. Liu, "Epigenetics: the missing link to understanding beta-cell dysfunction in the pathogenesis of type 2 diabetes," *Epigenetics*, vol. 7, pp. 841–852, 2012.

